INIT.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 18:29):

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system...

Stats
Dzisiejszy wolumen	22 443.00
Średni wolumen	27 925.00
Kapitalizacja rynkowa	498.49M
EPS	SEK0 ( 2024-02-22 )
Następna data zysków	( SEK0 ) 2024-05-10
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-10.35
ATR14	SEK0.0750 (0.80%)

Wolumen Korelacja

Długi: 0.10 (neutral)

Krótki: 0.62 (weak)

Signal:(52.733) Neutral

Initiator Pharma A/S Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Initiator Pharma A/S Korelacja - Waluta/Towar

0.40
( neutral )

0.21
( neutral )

0.00
( neutral )

0.32
( neutral )

0.60
( weak )

-0.42
( neutral )

Initiator Pharma A/S Finanse

Annual	2023
Przychody:	SEK0
Zysk brutto:	SEK-23 412.00 (0.00 %)
EPS:	SEK-0.000400

FY	2023
Przychody:	SEK0
Zysk brutto:	SEK-23 412.00 (0.00 %)
EPS:	SEK-0.000400

FY	2022
Przychody:	SEK0
Zysk brutto:	SEK-38 425.00 (0.00 %)
EPS:	SEK-0.720

FY	2021
Przychody:	SEK0.00
Zysk brutto:	SEK-21.63M (0.00 %)
EPS:	SEK-0.531

Financial Reports:

No articles found.

Initiator Pharma A/S

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.

Aktualne aktualizacje dla Initiator Pharma A/S [INIT.ST]

Upcoming Earnings Alert